APAC Tumor Ablation Market - Industry Trends and Forecast to 2030

TABLE OF CONTENT

1 INTRODUCTION 35
1.1 OBJECTIVES OF THE STUDY 35
1.2 MARKET DEFINITION 35
1.3 OVERVIEW OF THE ASIA PACIFIC TUMOR ABLATION MARKET 35
1.4 CURRENCY AND PRICING 37
1.5 LIMITATIONS 37
1.6 MARKETS COVERED 37
2 MARKET SEGMENTATION 40
2.1 MARKETS COVERED 40
2.2 GEOGRAPHICAL SCOPE 41
2.3 YEARS CONSIDERED FOR THE STUDY 42
2.4 Cognate Lifesciences TRIPOD DATA VALIDATION MODEL 43
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 46
2.6 MULTIVARIATE MODELLING 47
2.7 TYPE SEGMENT LIFELINE CURVE 48
2.8 MARKET END USERS COVERAGE GRID 49
2.9 Cognate Lifesciences MARKET POSITION GRID 50
2.10 VENDOR SHARE ANALYSIS 51
2.11 SECONDARY SOURCES 52
2.12 ASSUMPTIONS 52
3 EXECUTIVE SUMMARY 53
4 PREMIUM INSIGHTS 55
4.1 PESTEL ANALYSIS 56
4.2 PORTER'S FIVE FORCES MODEL 57
5 REGULATORY FRAMEWORK 58
5.1 REGULATORY SCENARIO IN CHINA 58
5.2 REGULATORY SCENARIO IN AUSTRALIA 59
6 MARKET OVERVIEW 60
6.1 DRIVERS 62
6.1.1 RISING PREVALENCE OF CANCER ASIA PACIFICLY 62
6.1.2 INCREASING INCLINATION OF SURGEONS AND PATIENTS TOWARD MINIMALLY INVASIVE PROCEDURES 62
6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS 63
6.1.4 INCREASING AWARENESS AND EDUCATION 63
6.2 RESTRAINTS 64
6.2.1 REGULATORY HURDLES FOR APPROVAL 64
6.2.2 LIMITED CLINICAL EVIDENCE 64
6.3 OPPORTUNITIES 65
6.3.1 FAVORABLE REIMBURSEMENT SCENARIO 65
6.3.2 STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 65
6.4 CHALLENGES 66
6.4.1 TECHNICAL CHALLENGES IN TARGETING THE TUMOR 66
6.4.2 COMPETITION FROM ALTERNATIVE TREATMENT MODALITIES 66
7 ASIA PACIFIC TUMOR ABLATION MARKET, BY TYPE 67
7.1 OVERVIEW 68
7.2 THERMAL ABLATION 71
7.2.1 TUMOR ABLATION SYSTEMS 72
7.2.1.1 RADIOFREQUENCY 73
7.2.1.1.1 BIPOLAR 73
7.2.1.1.2 MULTIPOLAR 73
7.2.2 IMAGE GUIDANCE PRODUCTS AND ACCESSORIES 73
7.2.2.1 CT 74
7.2.2.2 MR IMAGING 74
7.2.2.3 FLUOROSCOPY 74
7.2.2.4 OTHERS 74
7.2.2.5 MICROWAVE 74
7.2.2.6 CRYOABLATION 74
7.2.2.7 HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU) 74
7.2.2.8 LASER 74
7.3 CHEMICAL ABLATION 74
7.3.1 ETHANOL 75
7.3.2 ACETIC ACID 75
8 ASIA PACIFIC TUMOR ABLATION MARKET, BY TYPES OF TREATMENT 76
8.1 OVERVIEW 77
8.2 PERCUTANEOUS 80
8.2.1 BREAST CANCER 81
8.2.2 LUNG CANCER 81
8.2.3 PROSTATE CANCER 81
8.2.4 LIVER CANCER 81
8.2.5 KIDNEY CANCER 81
8.2.6 OTHER CANCERS 81 
8.3 LAPAROSCOPY 81
8.3.1 BREAST CANCER 82
8.3.2 LUNG CANCER 82
8.3.3 PROSTATE CANCER 82
8.3.4 LIVER CANCER 82
8.3.5 KIDNEY CANCER 83
8.3.6 OTHER CANCERS 83
8.4 SURGICAL 83
8.4.1 BREAST CANCER 84
8.4.2 LUNG CANCER 84
8.4.3 PROSTATE CANCER 84
8.4.4 LIVER CANCER 84
8.4.5 KIDNEY CANCER 84
8.4.6 OTHER CANCERS 84
9 ASIA PACIFIC TUMOR ABLATION MARKET, BY CANCER TYPE 85
9.1 OVERVIEW 86
9.2 BREAST CANCER 89
9.3 LUNG CANCER 89
9.4 PROSTATE CANCER 90
9.5 LIVER CANCER 91
9.6 KIDNEY CANCER 92
9.7 BONE CANCER 93
9.8 OTHERS 94
10 ASIA PACIFIC TUMOR ABLATION MARKET, BY END USERS 95
10.1 OVERVIEW 96
10.2 HOSPITALS 99
10.3 ONCOLOGY CENTERS 99
10.4 OTHERS 100
11 ASIA PACIFIC TUMOR ABLATION MARKET, BY DISTRIBUTION CHANNEL 101
11.1 OVERVIEW 102
11.2 DIRECT TENDER 105
11.3 RETAIL SALES 105 
12 ASIA PACIFIC TUMOR ABLATION MARKET, BY REGION 107
12.1 ASIA PACIFIC 108
12.1.1 CHINA 118
12.1.2 JAPAN 123
12.1.3 INDIA 128
12.1.4 AUSTRALIA 133
12.1.5 SOUTH KOREA 138
12.1.6 INDONESIA 143
12.1.7 PHILIPPINES 148
12.1.8 THAILAND 153
12.1.9 MALAYSIA 158
12.1.10 SINGAPORE 163
12.1.11 REST OF ASIA-PACIFIC 168
13 ASIA PACIFIC TUMOR ABLATION MARKET, COMPANY LANDSCAPE 169
13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 169
14 SWOT ANALYSIS 170
15 COMPANY PROFILE 171
15.1 BOSTON SCIENTIFIC CORPORATION 171
15.1.1 COMPANY SNAPSHOT 171
15.1.2 REVENUE ANALYSIS 171
15.1.3 COMPANY SHARE ANALYSIS 172
15.1.4 PRODUCT PORTFOLIO 172
15.1.5 RECENT DEVELOPMENT 172
15.2 MEDTRONIC 173
15.2.1 COMPANY SNAPSHOT 173
15.2.2 REVENUE ANALYSIS 173
15.2.3 COMPANY SHARE ANALYSIS 174
15.2.4 PRODUCT PORTFOLIO 174
15.2.5 RECENT DEVELOPMENT 174
15.3 OLYMPUS 175
15.3.1 COMPANY SNAPSHOT 175
15.3.2 REVENUE ANALYSIS 175
15.3.3 COMPANY SHARE ANALYSIS 176
15.3.4 PRODUCT PORTFOLIO 176
15.3.5 RECENT DEVELOPMENT 176
15.4 STRYKER 177
15.4.1 COMPANY SNAPSHOT 177
15.4.2 REVENUE ANALYSIS 177
15.4.3 COMPANY SHARE ANALYSIS 178
15.4.4 PRODUCT PORTFOLIO 178
15.4.5 RECENT DEVELOPMENT 178
15.5 BIOTRONIK 179
15.5.1 COMPANY SNAPSHOT 179
15.5.2 COMPANY SHARE ANALYSIS 179
15.5.3 PRODUCT PORTFOLIO 180
15.5.4 RECENT DEVELOPMENT 180
15.6 ANGIODYNAMICS. 181
15.6.1 COMPANY SNAPSHOT 181
15.6.2 REVENUE ANALYSIS 181
15.6.3 PRODUCT PORTFOLIO 182
15.6.4 RECENT DEVELOPMENT 182
15.7 BIOVENTUS LLC. 183
15.7.1 COMPANY SNAPSHOT 183
15.7.2 PRODUCT PORTFOLIO 183
15.7.3 RECENT DEVELOPMENT 183
15.8 BVM MEDICAL LIMITED 184
15.8.1 COMPANY SNAPSHOT 184
15.8.2 PRODUCT PORTFOLIO 184
15.8.3 RECENT DEVELOPMENT 184
15.9 EDAP TMS 185
15.9.1 COMPANY SNAPSHOT 185
15.9.2 REVENUE ANALYSIS 185
15.9.3 PRODUCT PORTFOLIO 186
15.9.4 RECENT DEVELOPMENT 186
15.10 ETHICON, INC. 187
15.10.1 COMPANY SNAPSHOT 187
15.10.2 PRODUCT PORTFOLIO 187
15.10.3 RECENT DEVELOPMENT 187
15.11 HEALTHTRONICS, INC. 188
15.11.1 COMPANY SNAPSHOT 188
15.11.2 PRODUCT PORTFOLIO 188
15.11.3 RECENT DEVELOPMENT 188 
15.12 ICECURE MEDICAL 189
15.12.1 COMPANY SNAPSHOT 189
15.12.2 REVENUE ANALYSIS 189
15.12.3 PRODUCT PORTFOLIO 190
15.12.4 RECENT DEVELOPMENT 190
15.13 INSIGHTEC. 191
15.13.1 COMPANY SNAPSHOT 191
15.13.2 PRODUCT PORTFOLIO 191
15.13.3 RECENT DEVELOPMENT 191
15.14 INTEGRA LIFESCIENCES 192
15.14.1 COMPANY SNAPSHOT 192
15.14.2 REVENUE ANALYSIS 192
15.14.3 PRODUCT PORTFOLIO 193
15.14.4 RECENT DEVELOPMENT 193
15.15 MERIT MEDICAL SYSTEMS. 194
15.15.1 COMPANY SNAPSHOT 194
15.15.2 REVENUE ANALYSIS 194
15.15.3 PRODUCT PORTFOLIO 195
15.15.4 RECENT DEVELOPMENT 195
15.16 SONABLATE CORP. 196
15.16.1 COMPANY SNAPSHOT 196
15.16.2 PRODUCT PORTFOLIO 196
15.16.3 RECENT DEVELOPMENT 196
15.17 TERUMO EUROPE NV 197
15.17.1 COMPANY SNAPSHOT 197
15.17.2 PRODUCT PORTFOLIO 197
15.17.3 RECENT DEVELOPMENT 197
16 QUESTIONNAIRE 198
17 RELATED REPORTS 201